drugset / Trial / NCT05616052

Comparison of Body Weight Change Through Different Smeglutide Administration Methods

NCT05616052

Phase 4 Unknown 80 enrolled Huashan Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

Investigators determined to detect the effect of smeglutide on body weight and metabolic indexes among overweight and obese participants through two different dosing programs.

Timeline

Start
2022-12-01
Primary completion
2023-12-01
Completion
2023-12-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Semaglutide Peptide 1 mg

Indications

No indication recorded.